The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination
Open accessAbstract
Objective: We characterised the clinical course, treatment and outcomes in 59 patients with relapsing myelin oligodendrocyte glycoprotein (MOG) antibody-associated demyelination. Methods: We evaluated clinical phenotypes, annualised relapse rates (ARR) prior and on immunotherapy and Expanded Disability Status Scale (EDSS), in 218 demyelinating episodes from 33 paediatric and 26 adult patients. Results: The most common initial presentation in the cohort was optic neuritis (ON) in 54% (bilateral (BON) 32%, unilateral (UON) 22%), followed by acute disseminated encephalomyelitis (ADEM) (20%), which occurred exclusively in children. ON was the dominant phenotype (UON 35%, BON 19%) of all clinical episodes. 109/226 (48%) MRIs had no brain lesions. Patients were steroid responsive, but 70% of episodes treated with oral prednisone relapsed, particularly at doses <10 mg daily or within 2 months of cessation. Immunotherapy, including maintenance prednisone (P=0.0004), intravenous immunoglobulin, rituximab and mycophenolate, all reduced median ARRs on-treatment. Treatment failure rates were lower in patients on maintenance steroids (5%) compared with non-steroidal maintenance immunotherapy (38%) (P=0.016). 58% of patients experienced residual disability (average follow-up 61 months, visual loss in 24%). Patients with ON were less likely to have sustained disability defined by a final EDSS of ≥2 (OR 0.15, P=0.032), while those who had any myelitis were more likely to have sustained residual deficits (OR 3.56, P=0.077). Conclusion: Relapsing MOG antibody-associated demyelination is strongly associated with ON across all age groups and ADEM in children. Patients are highly responsive to steroids, but vulnerable to relapse on steroid reduction and cessation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001729 · Cited by 4,649
New Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
Ruiter, A. M., Meilof, J. F., Somanje-Bolweg, R. R. J., van Gorsel, E., & Kalkers, N. F. (2017) · Case Reports in Neurology · doi:10.1159/000455942 · Cited by 1,762
Krupp, L. B., Tardieu, M., Amato, M. P., Banwell, B., Chitnis, T., Dale, R. C., Ghezzi, A., Hintzen, R., Kornberg, A., Pohl, D., et al. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513484547 · Cited by 1,130
Self-citationin cooperation with the Neuromyelitis Optica Study Group (NEMOS), Jarius, S., Ruprecht, K., Kleiter, I., Borisow, N., Asgari, N., Pitarokoili, K., Pache, F., Stich, O., Beume, L.-A., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0718-0 · Cited by 899
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders
Sato, D. K., Callegaro, D., Lana-Peixoto, M. A., Waters, P. J., Jorge, F. M. D. H., Takahashi, T., Nakashima, I., Apostolos-Pereira, S. L., Talim, N., Simm, R. F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000101 · Cited by 850
Dale, R. C. (2000) · Brain · doi:10.1093/brain/123.12.2407 · Cited by 703
Self-citationKitley, J., Waters, P., Woodhall, M., Leite, M. I., Murchison, A., George, J., Küker, W., Chandratre, S., Vincent, A., & Palace, J. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5857 · Cited by 597
Neuromyelitis Optica Study Group (NEMOS), Trebst, C., Jarius, S., Berthele, A., Paul, F., Schippling, S., Wildemann, B., Borisow, N., Kleiter, I., Aktas, O., et al. (2014) · Journal of Neurology · doi:10.1007/s00415-013-7169-7 · Cited by 595
MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy
Ogawa, R., Nakashima, I., Takahashi, T., Kaneko, K., Akaishi, T., Takai, Y., Sato, D. K., Nishiyama, S., Misu, T., Kuroda, H., et al. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000322 · Cited by 436
Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses
Kleiter, I., Gahlen, A., Borisow, N., Fischer, K., Wernecke, K., Wegner, B., Hellwig, K., Pache, F., Ruprecht, K., Havla, J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24554 · Cited by 432
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein
O'Connor, K. C., McLaughlin, K. A., De Jager, P. L., Chitnis, T., Bettelli, E., Xu, C., Robinson, W. H., Cherry, S. V., Bar-Or, A., Banwell, B., et al. (2007) · Nature Medicine · doi:10.1038/nm1488 · Cited by 416
Self-citationBrunner, C., Lassmann, H., Waehneldt, T. V., Matthieu, J., & Linington, C. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb10930.x · Cited by 409
Ramanathan, S., Prelog, K., Barnes, E. H., Tantsis, E. M., Reddel, S. W., Henderson, A. P., Vucic, S., Gorman, M. P., Benson, L. A., Alper, G., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515593406 · Cited by 384
Self-citationSchluesener, H. J., Sobel, R. A., Linington, C., & Weiner, H. L. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.12.4016 · Cited by 371
Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease
Dale, R. C., Brilot, F., Duffy, L. V., Twilt, M., Waldman, A. T., Narula, S., Muscal, E., Deiva, K., Andersen, E., Eyre, M. R., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000570 · Cited by 344
Self-citationBrilot, F., Dale, R. C., Selter, R. C., Grummel, V., Reddy Kalluri, S., Aslam, M., Busch, V., Zhou, D., Cepok, S., & Hemmer, B. (2009) · Annals of Neurology · doi:10.1002/ana.21916 · Cited by 322
Self-citationBaumann, M., Sahin, K., Lechner, C., Hennes, E. M., Schanda, K., Mader, S., Karenfort, M., Selch, C., Hausler, M., Eisenkolbl, A., et al. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308346 · Cited by 314
Mealy, M. A., Wingerchuk, D. M., Palace, J., Greenberg, B. M., & Levy, M. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5699 · Cited by 302
Kim, S.-H. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.154 · Cited by 295
Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica
Kleiter, I. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.216 · Cited by 294
Höftberger, R., Sepulveda, M., Armangue, T., Blanco, Y., Rostásy, K., Cobo Calvo, A., Olascoaga, J., Ramió-Torrentà, L., Reindl, M., Benito-León, J., et al. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458514555785 · Cited by 285
Min, J.-H., Kim, B. J., & Lee, K. H. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458511431973 · Cited by 280
Jurynczyk, M., Geraldes, R., Probert, F., Woodhall, M. R., Waters, P., Tackley, G., DeLuca, G., Chandratre, S., Leite, M. I., Vincent, A., et al. (2017) · Brain · doi:10.1093/brain/aww350 · Cited by 265
in cooperation with the Neuromyelitis Optica Study Group (NEMOS), Jarius, S., Kleiter, I., Ruprecht, K., Asgari, N., Pitarokoili, K., Borisow, N., Hümmert, M. W., Trebst, C., Pache, F., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0719-z · Cited by 252
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis
Ramanathan, S., Reddel, S. W., Henderson, A., Parratt, J. D. E., Barnett, M., Gatt, P. N., Merheb, V., Kumaran, R.-Y. A., Pathmanandavel, K., Sinmaz, N., et al. (2014) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000040 · Cited by 231
Self-citationAutoantibodies to MOG in a distinct subgroup of adult multiple sclerosis
Spadaro, M., Gerdes, L. A., Krumbholz, M., Ertl-Wagner, B., Thaler, F. S., Schuh, E., Metz, I., Blaschek, A., Dick, A., Brück, W., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000257 · Cited by 206
Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients
Kremer, L., Mealy, M., Jacob, A., Nakashima, I., Cabre, P., Bigi, S., Paul, F., Jarius, S., Aktas, O., Elsone, L., et al. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458513507822 · Cited by 196
Diagnostic algorithm for relapsing acquired demyelinating syndromes in children
Hacohen, Y., Mankad, K., Chong, W. K., Barkhof, F., Vincent, A., Lim, M., Wassmer, E., Ciccarelli, O., & Hemingway, C. (2017) · Neurology · doi:10.1212/wnl.0000000000004117 · Cited by 190
Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis
Rostasy, K., Mader, S., Schanda, K., Huppke, P., Gärtner, J., Kraus, V., Karenfort, M., Tibussek, D., Blaschek, A., Bajer-Kornek, B., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.2956 · Cited by 182
Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton
Dale, R. C., Tantsis, E. M., Merheb, V., Kumaran, R.-Y. A., Sinmaz, N., Pathmanandavel, K., Ramanathan, S., Booth, D. R., Wienholt, L. A., Prelog, K., et al. (2014) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000012 · Cited by 173
Self-citationBaumann, M., Hennes, E.-M., Schanda, K., Karenfort, M., Kornek, B., Seidl, R., Diepold, K., Lauffer, H., Marquardt, I., Strautmanis, J., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516631038 · Cited by 167
Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease
Juryńczyk, M., Tackley, G., Kong, Y., Geraldes, R., Matthews, L., Woodhall, M. R., Waters, P. J., Küker, W., Craner, M. J., Weir, A., et al. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314005 · Cited by 165
Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases
Hyun, J., Woodhall, M. R., Kim, S., Jeong, I. H., Kong, B. S., Kim, G., Kim, Y., Park, M. S., Irani, S. R., Waters, P. J., et al. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-315998 · Cited by 160
Sepúlveda, M., Armangué, T., Martínez‐Hernández, E., Arrambide, G., Solà‐Valls, N., Sabater, L., Téllez, N., Midaglia, L. S., Ariño, H., Peschl, P., et al. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8147-7 · Cited by 136
Jeong, I. H., Park, B., Kim, S., Hyun, J., Joo, J., & Kim, H. J. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515587752 · Cited by 128
Montcuquet, A., Collongues, N., Papeix, C., Zéphir, H., Audoin, B., Laplaud, D. A., Bourre, B., Brochet, B., Camdessanché, J., Labauge, P. M., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516678474 · Cited by 121
Greenberg, B. M., Graves, D. F., Remington, G. M., Hardeman, P., Mann, M., Karandikar, N. J., Stüve, O., Monson, N. L., & Frohman, E. M. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458511432896 · Cited by 117
Cobo‐Calvo, Á., Sepúlveda, M., Bernard‐Valnet, R., Ruiz, A., Brassat, D., Martínez‐Yélamos, S., Saiz, A., & Marignier, R. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515591071 · Cited by 91
Kumar, N., Graven, K., Joseph, N., Johnson, J., Fulton, S. A., Hostoffer, R., & Abboud, H. (2019) · International Journal of MS Care · doi:10.7224/1537-2073.2018-104 · Cited by 37
Cited by
Banwell, B., Bennett, J. L., Marignier, R., Kim, H. J., Brilot, F., Flanagan, E. P., Ramanathan, S., Waters, P., Tenembaum, S., Graves, J. S., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00431-8 · Cited by 1,246
Self-citationB cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
Myelin oligodendrocyte glycoprotein antibodies in neurological disease
Reindl, M., & Waters, P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0112-x · Cited by 626
Myelin-oligodendrocyte glycoprotein antibody-associated disease
Marignier, R., Hacohen, Y., Cobo-Calvo, A., Pröbstel, A.-K., Aktas, O., Alexopoulos, H., Amato, M.-P., Asgari, N., Banwell, B., Bennett, J., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00218-0 · Cited by 543
Self-citationJarius, S., Paul, F., Weinshenker, B. G., Levy, M., Kim, H. J., & Wildemann, B. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0214-9 · Cited by 478
Metadata
- Authors
- Ramanathan, S., Mohammad, S., Tantsis, E., Nguyen, T. K., Merheb, V., Fung, V. S. C., White, O. B., Broadley, S., Lechner-Scott, J., Vucic, S., Henderson, A. P. D., Barnett, M. H., Reddel, S. W., Brilot, F., & Dale, R. C.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2017-11-15
- Volume
- 89
- Issue
- 2
- Pages
- 127-137
- ISSN
- 0022-3050 (ISSN-L)
- 1468-330X
- OpenAlex
- W2770558705
- Cited by
- 572
- References
- 42
- FWCI
- 34.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.